More MS news articles for June 2000

Pathobiotek Announced Preliminary Results of a Nutrient Study

Tuesday June 27, 2:56 pm Eastern Time
Company Press Release
SOURCE: Pathobiotek Diagnostics Inc.

HOUSTON, June 27 /PRNewswire/ -- Pathobiotek Diagnostics Inc. (OTC Bulletin Board: PBTK - news;, a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, announced today promising results of a pilot study that examined the effect of Pathobiotek's supplemental formula on patients diagnosed with MS and CFS.

Preliminary data obtained from patient surveys and bacterial quantitation indicated a positive effect of Pathobiotek's supplemental formula. This Pathobiotek formula is the result of seven years of research. We observed reduced visual bacterial counts confirmed by RT-PCR quantitation and patient reports of moderate relief of several symptoms.

No definitive claims can be made from this pilot study. A larger and more comprehensive testing to add statistical significance is currently being conducted since the initial results were obtained from a small group of research subjects.

Pathobiotek's supplemental formula will soon be made available. No claims will be made regarding the efficacy of this new product.

Pathobiotek develops products to license to qualified partners for the diagnosis and monitoring of treatment for multiple sclerosis and other immune disorders. The Company is concentrating its resources and strengths for the benefit of those suffering with MS and other immune disorders, its shareholders and employees.

Additional information on Pathobiotek Diagnostics Inc. can be obtained at

Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, risk inherent in the company's domestic and international operations, imprecision in estimating product reserves and the company's ability to replace and expand its holdings.

SOURCE: Pathobiotek Diagnostics Inc.